# Camrelizumab Combined With Famitinib Malate and Chemotherapy for Treatment of Recurrent/ Metastatic Cervical Cancer

> **NCT07627620** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Hunan Cancer Hospital** · enrollment: 54 (estimated)

## Conditions studied

- Cervical Cancer

## Interventions

- **DRUG:** Camrelizumab
- **DRUG:** Famitinib Malate
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT07627620
- **Lead sponsor:** Hunan Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-30
- **Primary completion:** 2027-09-30
- **Final completion:** 2029-03-30
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2026-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07627620

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07627620, "Camrelizumab Combined With Famitinib Malate and Chemotherapy for Treatment of Recurrent/ Metastatic Cervical Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07627620. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*